What is Rocklatan?
It’s a drop used once daily to lower IOP and it’s a combo of two drugs, latanoprost and Rhopressa. Rhopressa was recently FDA approved at the end of 2017.
How does Rocklatan work?
Two main ways:
1. Increases uveoscleral outflow – latanoprost works here.
2. Increases outflow through the trabecular meshwork by inhibiting Rho Kinase (ROCK) – Rhopressa works here.
What are the side effects?
The most common ocular adverse reaction is conjunctival hyperemia (59%) but others include instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%).
How much more IOP lowering do we get with this combo drop?
According to their studies, 1 to 3mmHg more than monotherapy with either Rhopressa or latanoprost 0.005% alone. In their clinical trials, more than 60% of patients using Rocklatan achieved an IOP reduction of 30% or more.
When can we get it?
The company plans to launch in the second quarter of 2019. (via)